Sökning: "Tumörer"
Visar resultat 11 - 15 av 227 avhandlingar innehållade ordet Tumörer.
11. MOLECULAR PROFILING OF UROTHELIAL CARCINOMA
Sammanfattning : The general aim of this thesis was to molecularly characterize urothelial carcinoma (UC) at the transcriptional level using gene expression microarrays to improve the classification and pathogenetic understanding of this disease. In the first two studies (Articles I and II), gene expression profiling was used to study dysregulated transcriptional networks in a large cohort of UCs. LÄS MER
12. Neural Progenitor Cells in malignancy and injury of the brain. A Trojan Horse fro gliomas?
Sammanfattning : Gliomas are neoplasms arising in the central nervous system (CNS), and constitute the most common primary brain tumor. They are classified depending on the grade and morphology, from grade I, pilocytic astrocytoma, to grade IV, glioblastoma multiforme (GBM). Glioblastomas constitute a great challenge in treatment due to their disseminating nature. LÄS MER
13. Profiling the cancer proteome
Sammanfattning : Cancer is a complex and heterogeneous disease where cells have started to grow uncontrolled and this disease remains a major health problem. Because of diffuse symptoms it often presents at a late stage. LÄS MER
14. Extratumoral effects of highly aggressive prostate cancer
Sammanfattning : Prostate cancer (PC) is the most common cancer in Sweden. Most patients have slow growing tumors that will not cause them any harm within their lifetime, but some have aggressive tumors and will die from their disease. LÄS MER
15. Tamoxifen response in primary breast cancer with special reference to tumour-specific VEGF-A and VEGFR2
Sammanfattning : Background: Treatment of primary breast cancer is individualised and adjuvant systemic treatment is delivered to most patients after surgery. Oestrogen receptor (ER) status and progesterone receptor status (PR) can define patients who would benefit from adjuvant endocrine therapy with tamoxifen (TAM) alone or as chemo-endocrine therapy. LÄS MER